Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M.

CMAJ. 2019 Aug 26;191(34):E932-E939. doi: 10.1503/cmaj.190274.

2.

A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine.

Gilca V, Sauvageau C, De Serres G.

Vaccine. 2019 Jul 26;37(32):4422-4423. doi: 10.1016/j.vaccine.2019.06.028. No abstract available.

PMID:
31319931
3.

EXamining the knowledge, Attitudes and experiences of Canadian seniors Towards influenza (the EXACT survey).

Andrew MK, Gilca V, Waite N, Pereira JA.

BMC Geriatr. 2019 Jun 26;19(1):178. doi: 10.1186/s12877-019-1180-5.

4.

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3.

PMID:
31017850
5.

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM.

Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19.

PMID:
30467063
6.

Herpes Zoster Burden in Canadian Provinces: A Narrative Review and Comparison with Quebec Provincial Data.

Letellier MC, Amini R, Gilca V, Trudeau G, Sauvageau C.

Can J Infect Dis Med Microbiol. 2018 Oct 21;2018:3285327. doi: 10.1155/2018/3285327. eCollection 2018. Review.

7.

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.

PMID:
30314913
8.

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(2):503-507. doi: 10.1080/21645515.2018.1522469. Epub 2018 Sep 27.

9.

Canadian older adults' perceptions of effectiveness and value of regular and high-dose influenza vaccines.

Pereira JA, Gilca V, Waite N, Andrew MK.

Hum Vaccin Immunother. 2019;15(2):487-495. doi: 10.1080/21645515.2018.1520580. Epub 2018 Sep 21.

PMID:
30204043
10.

Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis.

Tatar O, Thompson E, Naz A, Perez S, Shapiro GK, Wade K, Zimet G, Gilca V, Janda M, Kahn J, Daley E, Rosberger Z.

Prev Med. 2018 Nov;116:40-50. doi: 10.1016/j.ypmed.2018.08.034. Epub 2018 Aug 31.

PMID:
30172799
11.

Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.

Gilca V, Salmerón-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, Lazcano-Ponce E.

Vaccine. 2018 Aug 6;36(32 Pt A):4800-4805. doi: 10.1016/j.vaccine.2018.02.004. Epub 2018 Jun 7.

12.

Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.

Goggin P, Sauvageau C, Gilca V, Defay F, Lambert G, Mathieu-C S, Guenoun J, Comète E, Coutlée F.

Hum Vaccin Immunother. 2018 Jan 2;14(1):118-123. doi: 10.1080/21645515.2017.1385688. Epub 2017 Dec 13.

13.

Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.

Deceuninck G, Sauvageau C, Gilca V, Boulianne N, De Serres G.

Expert Rev Vaccines. 2018 Jan;17(1):99-102. doi: 10.1080/14760584.2018.1388168. Epub 2017 Oct 13.

PMID:
28972438
14.

Untangling the psychosocial predictors of HPV vaccination decision-making among parents of boys.

Perez S, Tatar O, Gilca V, Shapiro GK, Ogilvie G, Guichon J, Naz A, Rosberger Z.

Vaccine. 2017 Aug 24;35(36):4713-4721. doi: 10.1016/j.vaccine.2017.07.043. Epub 2017 Jul 27.

PMID:
28757059
15.

Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.

Brousseau N, Murphy DG, Gilca V, Larouche J, Mandal S, Tedder RS.

J Med Case Rep. 2017 Apr 17;11(1):111. doi: 10.1186/s13256-017-1264-9.

16.

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N.

Clin Infect Dis. 2017 May 1;64(9):1263-1267. doi: 10.1093/cid/cix154.

PMID:
28207068
17.
18.

Global travel patterns and risk of measles in Ontario and Quebec, Canada: 2007-2011.

Wilson SE, Khan K, Gilca V, Miniota J, Deeks SL, Lim G, Eckhardt R, Bolotin S, Crowcroft NS.

BMC Infect Dis. 2015 Aug 18;15:341. doi: 10.1186/s12879-015-1039-0.

19.

Short- and Long-Term Effects of a Challenge Dose of Hepatitis B Vaccine in Individuals With and Without Residual Anti-HBs.

Gilca V, Boulianne N, Murphy D, De Serres G.

Infect Control Hosp Epidemiol. 2015 Sep;36(9):1119-20. doi: 10.1017/ice.2015.147. Epub 2015 Jun 25. No abstract available.

PMID:
26108991
20.

Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.

Porgo TV, Gilca V, De Serres G, Tremblay M, Skowronski D.

BMC Infect Dis. 2015 Jun 12;15:227. doi: 10.1186/s12879-015-0979-8.

21.

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.

Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.

Hum Vaccin Immunother. 2015;11(3):732-8. doi: 10.1080/21645515.2015.1011570.

22.

Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results.

Krawczyk A, Knäuper B, Gilca V, Dubé E, Perez S, Joyal-Desmarais K, Rosberger Z.

Hum Vaccin Immunother. 2015;11(2):322-9. doi: 10.1080/21645515.2014.1004030.

23.

Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.

Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M.

Hum Vaccin Immunother. 2014;10(8):2438-45. doi: 10.4161/hv.29617.

24.

Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M.

Hum Vaccin Immunother. 2013 Aug;9(8):1685-90. doi: 10.4161/hv.25015. Epub 2013 Jun 6.

25.

The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P.

PLoS One. 2012;7(11):e50659. doi: 10.1371/journal.pone.0050659. Epub 2012 Nov 29.

26.

Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M.

Vaccine. 2013 Jan 7;31(3):448-51. doi: 10.1016/j.vaccine.2012.11.037. Epub 2012 Dec 1.

PMID:
23206974
27.

Determinants of parents' decision to vaccinate their children against rotavirus: results of a longitudinal study.

Dubé E, Bettinger JA, Halperin B, Bradet R, Lavoie F, Sauvageau C, Gilca V, Boulianne N.

Health Educ Res. 2012 Dec;27(6):1069-80. doi: 10.1093/her/cys088. Epub 2012 Aug 20.

PMID:
22907535
28.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

PMID:
22872731
29.

Clinicians' opinions on new vaccination programs implementation.

Dubé E, Gilca V, Sauvageau C, Bettinger JA, Boucher FD, McNeil S, Gemmill I, Lavoie F, Ouakki M, Boulianne N.

Vaccine. 2012 Jun 29;30(31):4632-7. doi: 10.1016/j.vaccine.2012.04.100. Epub 2012 May 11.

PMID:
22580354
30.

Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.

Skowronski DM, De Serres G, Janjua NZ, Gardy JL, Gilca V, Dionne M, Hamelin ME, Rhéaume C, Boivin G.

Euro Surveill. 2012 Jan 26;17(4). pii: 20066.

31.

[Seasonal H1N1: a worry on the competence, attitude and practices of nurses during the vaccination campaign].

Kiely M, Defay F, Sauvageau C, Gilca V, Guay M, Boulianne N, Dubé E.

Perspect Infirm. 2012 Jan-Feb;9(1):61-4. French. No abstract available.

PMID:
22295461
32.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
33.

Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.

Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S.

BMC Infect Dis. 2011 Sep 5;11:235. doi: 10.1186/1471-2334-11-235. Review.

34.

Acute otitis media and its prevention by immunization: a survey of Canadian pediatricians' knowledge, attitudes and beliefs.

Dubé E, Gilca V, Sauvageau C, Bradet R, Lavoie F, Boulianne N, Boucher FD, Bettinger JA, McNeil S, Gemmill I.

Hum Vaccin. 2011 Apr;7(4):429-35. Epub 2011 Apr 1.

PMID:
21441777
35.

Canadian paediatricians' opinions on rotavirus vaccination.

Dubé E, Gilca V, Sauvageau C, Bradet R, Bettinger JA, Boulianne N, Boucher FD, McNeil S, Gemmill I, Lavoie F.

Vaccine. 2011 Apr 12;29(17):3177-82. doi: 10.1016/j.vaccine.2011.02.044. Epub 2011 Mar 2.

PMID:
21376118
36.

Burden of acute otitis media on Canadian families.

Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R.

Can Fam Physician. 2011 Jan;57(1):60-5.

37.

A nationwide survey of past hepatitis A infections among Canadian adults.

Scheifele DW, De Serres G, Gilca V, Duval B, Milner R, Ho M, Ochnio JJ.

Vaccine. 2010 Jul 19;28(32):5174-8. doi: 10.1016/j.vaccine.2010.05.076. Epub 2010 Jun 15.

PMID:
20558251
38.

Canadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine.

Dubé E, Gilca V, Sauvageau C, Boulianne N, Boucher FD, Bettinger JA, McNeil S, Gemmill I, Lavoie F, Ouakki M.

BMC Res Notes. 2010 Apr 14;3:102. doi: 10.1186/1756-0500-3-102.

39.

Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Deceuninck G, Massé R, Duval B.

Hum Vaccin. 2010 Feb;6(2):212-8. Epub 2010 Feb 11.

PMID:
19946212
40.

Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later.

Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Massé R, Duval B.

Vaccine. 2009 Oct 9;27(43):6048-53. doi: 10.1016/j.vaccine.2009.07.100. Epub 2009 Aug 13.

PMID:
19683086
41.

Long-term immunogenicity of two pediatric doses of combined hepatitis A and B or monovalent hepatitis B vaccine in 8 to 10-year-old children and the effect of a challenge dose given seven years later.

Gilca V, Dionne M, Boulianne N, Murphy D, De Serres G.

Pediatr Infect Dis J. 2009 Oct;28(10):916-8. doi: 10.1097/INF.0b013e3181a3ad28.

PMID:
19672212
42.

New vaccines offering a larger spectrum of protection against acute otitis media: will parents be willing to have their children immunized?

Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R.

Int J Pediatr Otorhinolaryngol. 2009 Jul;73(7):987-91. doi: 10.1016/j.ijporl.2009.03.022. Epub 2009 May 6.

PMID:
19423171
43.

Attitudes of nurses toward current and proposed vaccines for public programs: a questionnaire survey.

Gilca V, Boulianne N, Dubé E, Sauvageau C, Ouakki M.

Int J Nurs Stud. 2009 Sep;46(9):1219-35. doi: 10.1016/j.ijnurstu.2009.02.013. Epub 2009 Apr 5.

PMID:
19349047
44.

[Vaccination against human papillomaviruses].

Duval B, Sauvageau C, Boulianne N, Gilca V; Comité sur l'immunisation du Québec.

Perspect Infirm. 2009 Jan-Feb;6(1):49-50, 52; quiz 46, 52. French. No abstract available.

PMID:
19341056
45.

Cervical cancer prevention by vaccination: nurses' knowledge, attitudes and intentions.

Duval B, Gilca V, Boulianne N, Pielak K, Halperin B, Simpson MA, Sauvageau C, Ouakki M, Dube E, Lavoie F.

J Adv Nurs. 2009 Mar;65(3):499-508. doi: 10.1111/j.1365-2648.2008.04900.x.

PMID:
19222647
46.

Setting priorities for new vaccination programs by using public health officers and immunization managers opinions.

Gilca V, Sauvageau C, McNeil S, Gemmill IM, Dionne M, Dobson S, Ouakki M, Lavoie F, Duval B.

Vaccine. 2008 Aug 5;26(33):4204-9. doi: 10.1016/j.vaccine.2008.05.061. Epub 2008 Jun 11.

PMID:
18582998
47.

Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M.

Pharmacoeconomics. 2008;26(1):17-32. Review.

PMID:
18088156
48.

Cost-utility of universal hepatitis A vaccination in Canada.

Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD.

Vaccine. 2007 Dec 12;25(51):8536-48. Epub 2007 Oct 23.

PMID:
17996339
49.

Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada.

Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M.

BMC Public Health. 2007 Oct 25;7:304.

50.

Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs.

Duval B, Gilca V, McNeil S, Dobson S, Money D, Gemmill IM, Sauvageau C, Lavoie F, Ouakki M.

Vaccine. 2007 Nov 7;25(45):7841-7. Epub 2007 Sep 14.

PMID:
17923173

Supplemental Content

Support Center